{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:43:31Z","timestamp":1781174611334,"version":"3.54.1"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>Supplemental Digital Content is available in the text<\/jats:p>","DOI":"10.1097\/hs9.0000000000000045","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T01:25:25Z","timestamp":1525483525000},"source":"Crossref","is-referenced-by-count":48,"title":["Long\u2010term Outcomes in Patients With Multiple Myeloma"],"prefix":"10.1002","volume":"2","author":[{"given":"Silvia G.R.","family":"Verelst","sequence":"first","affiliation":[{"name":"Department of Hematology Erasmus University Medical Center Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig M.","family":"Blommestein","sequence":"additional","affiliation":[{"name":"Erasmus School of Health Policy and Management Erasmus University Rotterdam Rotterdam The Netherlands"},{"name":"Comprehensive Cancer Organisation Utrecht The Netherlands"},{"name":"Institute for Medical Technology Assessment Erasmus University Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"De Groot","sequence":"additional","affiliation":[{"name":"Erasmus School of Health Policy and Management Erasmus University Rotterdam Rotterdam The Netherlands"},{"name":"Institute for Medical Technology Assessment Erasmus University Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Gonzalez\u2010McQuire","sequence":"additional","affiliation":[{"name":"Amgen (Europe) GmbH Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"DeCosta","sequence":"additional","affiliation":[{"name":"Amgen Ltd Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan B.","family":"de Raad","sequence":"additional","affiliation":[{"name":"Amgen BV Breda The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin A.","family":"Uyl\u2010de Groot","sequence":"additional","affiliation":[{"name":"Erasmus School of Health Policy and Management Erasmus University Rotterdam Rotterdam The Netherlands"},{"name":"Comprehensive Cancer Organisation Utrecht The Netherlands"},{"name":"Institute for Medical Technology Assessment Erasmus University Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus University Medical Center Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt297"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.027"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147381"},{"issue":"1","key":"e_1_2_6_6_1","first-page":"S228","article-title":"Multiple myeloma: treatment and survival in the era of novel agents","volume":"13","author":"Verelst SGR","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_2_6_7_1","unstructured":"Celgene Europe Ltd.Thalidomide Celgene summary of product characteristics. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000823\/WC500037050.pdf(Accessed July 21 2016)."},{"key":"e_1_2_6_8_1","unstructured":"Celgene Europe Ltd.Revlimid summary of product characteristics. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000717\/WC500056018.pdf(Accessed July 21 2016)."},{"key":"e_1_2_6_9_1","unstructured":"Janssen\u2010Cilag Ltd.Velcade summary of product characteristics. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000539\/WC500048471.pdf(Accessed July 21 2016)."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0260-4"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.4284.4284"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.07.218"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12571"},{"key":"e_1_2_6_14_1","first-page":"808","article-title":"Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato\u2010Oncology Association (HOVON)","volume":"149","author":"Lokhorst H","year":"2005","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_6_15_1","first-page":"150","article-title":"Richtlijnen behandeling multipel myeloom anno 2008","volume":"5","author":"Lokhorst HM","year":"2008","journal-title":"Ned Tijdschr Hematol"},{"key":"e_1_2_6_16_1","first-page":"84","article-title":"Richtlijnen behandeling plasmacelaandoeningen anno 2010","volume":"7","author":"Sonneveld P","year":"2010","journal-title":"Ned Tijdschr Hematol"},{"key":"e_1_2_6_17_1","first-page":"300","article-title":"Richtlijnen behandeling multipel myeloom 2012","volume":"9","author":"Zweegman S","year":"2012","journal-title":"Ned Tijdschr Hematol"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.03.1470"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_2_6_20_1","unstructured":"Astellas Pharma GmbH.Levact summary of product characteristics. Available from:http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1427431950045.pdf. (Accessed March 22 2017)."},{"key":"e_1_2_6_21_1","unstructured":"Celgene Europe Ltd.Imnovid summary of product characteristics. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002682\/WC500147717.pdf(Accessed March 6 2017)."},{"key":"e_1_2_6_22_1","unstructured":"Novartis Europharm Ltd.Farydak summary of product characteristics. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/003725\/WC500193298.pdf(Accessed July 21 2016)."},{"key":"e_1_2_6_23_1","unstructured":"Amgen.Kyprolis summary of product characteristics. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/003790\/WC500197692.pdf(Accessed September 5 2016)."},{"key":"e_1_2_6_24_1","unstructured":"Takeda Pharma.NINLARO summary of product characteristics. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/003844\/WC500217620.pdf(Accessed January 5 2017)."},{"key":"e_1_2_6_25_1","unstructured":"Janssen\u2010Cilag International NV.DARZALEX summary of product characteristics. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/004077\/WC500207296.pdf(Accessed July 21 2016)."},{"key":"e_1_2_6_26_1","unstructured":"Bristol\u2010Myers Squibb Pharma EEIG.Empliciti summary of product characteristics. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/003967\/WC500206673.pdf(Accessed August 16 2016)."},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.08.003"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-163329"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.402"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0638"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.9158"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408898"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0023"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222539"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8164"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/HS9.0000000000000045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T02:31:24Z","timestamp":1709865084000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/HS9.0000000000000045"}},"subtitle":["A Retrospective Analysis of the Dutch Population\u2010based HAematological Registry for Observational Studies (PHAROS)"],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1097\/HS9.0000000000000045"],"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000045","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"article-number":"e45"}}